The current coronavirus vaccines focus on the spike protein but the UK's Scancell believes it has a candidate that also targets the SARS-CoV-2 nucleocapsid protein which could help tackle existing and future variants.

The leaked abstract suggests remdesivir provides no benefits for patients - but analysts say conclusions are hard to draw from underpowered trial.

Fortress Biotech’s subsidiary will add the lentiviral gene therapy now in pair of Phase I/II trials to its pipeline. RXi partners with Karolinska to advance its self-delivering RNAi technology, while Avalon enlists Weill Cornell to enhance its CAR-T capabilities.

This week's roundup includes CEO appointments by Gadeta, Scancell and Zafgen, with various other high-level appointments by Malin Corporation, Cell Medica and Apeiron Biologics.